CN111247151A - 2,3-二氢-1h-吡咯嗪-7-甲酰胺类衍生物及其应用 - Google Patents

2,3-二氢-1h-吡咯嗪-7-甲酰胺类衍生物及其应用 Download PDF

Info

Publication number
CN111247151A
CN111247151A CN201980005380.9A CN201980005380A CN111247151A CN 111247151 A CN111247151 A CN 111247151A CN 201980005380 A CN201980005380 A CN 201980005380A CN 111247151 A CN111247151 A CN 111247151A
Authority
CN
China
Prior art keywords
application
pyrrolizine
dihydro
formamide derivatives
formamide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201980005380.9A
Other languages
English (en)
Other versions
CN111247151B (zh
Inventor
贺海鹰
夏建华
龚珍
黎健
陈曙辉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Original Assignee
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Medshine Discovery Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chia Tai Tianqing Pharmaceutical Group Co Ltd, Medshine Discovery Inc filed Critical Chia Tai Tianqing Pharmaceutical Group Co Ltd
Priority to CN202110947906.4A priority Critical patent/CN113549079A/zh
Publication of CN111247151A publication Critical patent/CN111247151A/zh
Application granted granted Critical
Publication of CN111247151B publication Critical patent/CN111247151B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

本申请涉及一种作为核蛋白抑制剂的2,3‑二氢‑1H‑吡咯嗪‑7‑甲酰胺类衍生物，以及在制备治疗HBV相关疾病的的药物中的应用。具体涉及式(Ⅱ)所示化合物、其异构体或其药学上可接受的盐。

Description

PCT国内申请，说明书已公开。

Claims (1)

  1. PCT国内申请，权利要求书已公开。
CN201980005380.9A 2018-05-25 2019-05-24 2,3-二氢-1h-吡咯嗪-7-甲酰胺类衍生物及其应用 Active CN111247151B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202110947906.4A CN113549079A (zh) 2018-05-25 2019-05-24 2,3-二氢-1h-吡咯嗪-7-甲酰胺类衍生物及其应用

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
CN201810528259 2018-05-25
CN2018105282591 2018-05-25
CN201810843225 2018-07-27
CN2018108432251 2018-07-27
CN201811189801 2018-10-12
CN2018111898011 2018-10-12
PCT/CN2019/088376 WO2019223791A1 (zh) 2018-05-25 2019-05-24 2,3-二氢-1h-吡咯嗪-7-甲酰胺类衍生物及其应用

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202110947906.4A Division CN113549079A (zh) 2018-05-25 2019-05-24 2,3-二氢-1h-吡咯嗪-7-甲酰胺类衍生物及其应用

Publications (2)

Publication Number Publication Date
CN111247151A true CN111247151A (zh) 2020-06-05
CN111247151B CN111247151B (zh) 2021-08-10

Family

ID=68616574

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202110947906.4A Pending CN113549079A (zh) 2018-05-25 2019-05-24 2,3-二氢-1h-吡咯嗪-7-甲酰胺类衍生物及其应用
CN201980005380.9A Active CN111247151B (zh) 2018-05-25 2019-05-24 2,3-二氢-1h-吡咯嗪-7-甲酰胺类衍生物及其应用

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN202110947906.4A Pending CN113549079A (zh) 2018-05-25 2019-05-24 2,3-二氢-1h-吡咯嗪-7-甲酰胺类衍生物及其应用

Country Status (10)

Country Link
US (1) US11891398B2 (zh)
EP (1) EP3805223A4 (zh)
JP (1) JP7333342B2 (zh)
KR (1) KR20210016402A (zh)
CN (2) CN113549079A (zh)
AU (1) AU2019272481B2 (zh)
CA (1) CA3101373A1 (zh)
PH (1) PH12020552017A1 (zh)
SG (1) SG11202011685QA (zh)
WO (1) WO2019223791A1 (zh)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113365999A (zh) * 2019-01-31 2021-09-07 正大天晴药业集团股份有限公司 含有吡咯并杂环的衣壳蛋白装配抑制剂
CN115697338A (zh) * 2020-06-10 2023-02-03 南京明德新药研发有限公司 甲基取代的苯并二噁唑类化合物及其应用

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2686740C2 (ru) 2014-06-11 2019-04-30 Венаторкс Фармасьютикалс, Инк. Ингибиторы бета-лактамазы
US11267826B2 (en) 2017-05-26 2022-03-08 VenatoRx Pharmaceuticals, Inc. Penicillin-binding protein inhibitors
WO2018218190A1 (en) 2017-05-26 2018-11-29 VenatoRx Pharmaceuticals, Inc. Penicillin-binding protein inhibitors
US11247965B2 (en) 2017-12-11 2022-02-15 VenatoRx Pharmaceuticals, Inc. Hepatitis B capsid assembly modulators
CN115974753A (zh) 2018-03-30 2023-04-18 正大天晴药业集团股份有限公司 含有n杂五元环化合物和用途
KR20210019489A (ko) 2018-06-11 2021-02-22 베나토알엑스 파마슈티컬스, 인크. B형 간염 캡시드 조립 조절제
WO2021098850A1 (zh) * 2019-11-22 2021-05-27 正大天晴药业集团股份有限公司 一种核蛋白抑制剂的晶型及其应用
CN116367834A (zh) 2020-11-05 2023-06-30 正大天晴药业集团股份有限公司 包含衣壳蛋白抑制剂和核苷类似物的药物组合

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101743246A (zh) * 2007-05-25 2010-06-16 F2G有限公司 作为抗真菌剂的2-氧代-2-(2-苯基-5，6，7，8-四氢-中氮茚-3-基)-乙酰胺衍生物及相关化合物
WO2018039531A1 (en) * 2016-08-26 2018-03-01 Gilead Sciences, Inc. Substituted pyrrolizine compounds and uses thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1505964B1 (en) 2002-05-17 2007-11-21 Merckle Gmbh Annelated pyrrole compounds as proton pump inhibitors for treating ulcer
US20060040945A1 (en) 2002-05-17 2006-02-23 Merckle Gmbh Annellated pyrrole compounds as proton pump inhibitors for treating ulcer
PT2514750E (pt) 2007-06-18 2014-01-23 Sunshine Lake Pharma Co Ltd Tiazolil dihidropirimidinas substituídas com bromo-fenilo
EA201892034A1 (ru) 2016-03-09 2019-04-30 Эмори Юниверсити Элиминация вируса гепатита в при помощи противовирусных агентов
CN108794487B (zh) 2017-05-04 2020-11-10 上海长森药业有限公司 双并环类核衣壳抑制剂和其作为药物用于治疗乙型肝炎的用途
CN111788204B (zh) * 2018-02-26 2023-05-05 吉利德科学公司 作为hbv复制抑制剂的取代吡咯嗪化合物
CN115974753A (zh) 2018-03-30 2023-04-18 正大天晴药业集团股份有限公司 含有n杂五元环化合物和用途
KR20210019489A (ko) * 2018-06-11 2021-02-22 베나토알엑스 파마슈티컬스, 인크. B형 간염 캡시드 조립 조절제
EA202092159A1 (ru) 2019-01-25 2020-12-15 Чиа Тай Тянцин Фармасьютикал Груп Ко., Лтд. Содержащий n-гетероциклическое пятичленное кольцо ингибитор сборки капсидного белка, его фармацевтическая композиция и их применение

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101743246A (zh) * 2007-05-25 2010-06-16 F2G有限公司 作为抗真菌剂的2-氧代-2-(2-苯基-5，6，7，8-四氢-中氮茚-3-基)-乙酰胺衍生物及相关化合物
WO2018039531A1 (en) * 2016-08-26 2018-03-01 Gilead Sciences, Inc. Substituted pyrrolizine compounds and uses thereof

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113365999A (zh) * 2019-01-31 2021-09-07 正大天晴药业集团股份有限公司 含有吡咯并杂环的衣壳蛋白装配抑制剂
CN113365999B (zh) * 2019-01-31 2023-04-14 正大天晴药业集团股份有限公司 含有吡咯并杂环的衣壳蛋白装配抑制剂
CN115697338A (zh) * 2020-06-10 2023-02-03 南京明德新药研发有限公司 甲基取代的苯并二噁唑类化合物及其应用

Also Published As

Publication number Publication date
EP3805223A1 (en) 2021-04-14
CN113549079A (zh) 2021-10-26
JP7333342B2 (ja) 2023-08-24
PH12020552017A1 (en) 2021-06-28
CN111247151B (zh) 2021-08-10
EP3805223A4 (en) 2021-12-22
US20220204510A1 (en) 2022-06-30
SG11202011685QA (en) 2020-12-30
US11891398B2 (en) 2024-02-06
WO2019223791A1 (zh) 2019-11-28
JP2021525267A (ja) 2021-09-24
CA3101373A1 (en) 2019-11-28
KR20210016402A (ko) 2021-02-15
AU2019272481A1 (en) 2020-12-17
AU2019272481B2 (en) 2024-03-21

Similar Documents

Publication Publication Date Title
CN111247151A (zh) 2,3-二氢-1h-吡咯嗪-7-甲酰胺类衍生物及其应用
PH12019501688A1 (en) Pyridine derivative as ask1 inhibitor and preparation method and use thereof
ZA202006378B (en) N-heterocyclic five-membered ring-containing capsid protein assembly inhibitor, pharmaceutical composition thereof, and use thereof
EA038122B9 (ru) Ингибитор поверхностного антигена вируса гепатита b
WO2016109689A3 (en) Derivatives and methods of treating hepatitis b infections
JP2016515561A5 (zh)
NZ631738A (en) (hetero) arylacetamide derivatives as antiretroviral agents
SG11201901894TA (en) Anti-influenza virus pyrimidine derivatives
CN108026053A8 (zh) 作为mIDH1抑制剂的稠合的咪唑类化合物
WO2012125926A3 (en) Tetracyclic xanthene derivatives and methods of use thereof for the treatment of viral diseases
NZ628445A (en) Antiviral compounds with a heterotricycle moiety
MX2019003099A (es) Composicion farmaceutica.
WO2019178191A8 (en) O-glycoprotein-2-acetamido-2-deoxy-3-d-glycopyranosidase inhibitors
AU2016229966A8 (en) Beta-D-2'-deoxy-2'alpha-fluoro-2'-beta-C-substituted-2-modified-N6-substituted purine nucleotides for HCV treatment
EA201992771A1 (ru) Ингибитор поверхностного антигена вируса гепатита b
JP2017519817A5 (zh)
JP2017529357A5 (zh)
JP2005536503A5 (zh)
MA56534A (fr) Administration par nanoporteurs glucidiques, de vaccins contre le virus de l'hépatite b (vhb)
DK1594885T3 (da) Lægemiddel til vækstinhibering af tumorer
WO2017161133A8 (en) N-hydroxyisoquinolinedione inhibitors of hbv replication
WO2016195522A3 (en) Antiviral composition
PH12019502544A1 (en) Derivatives of resiquimod
WO2019191586A3 (en) Irradiation-inactivated poliovirus, compositions including the same, and methods of preparation
MX2021003232A (es) Inhibidores de o-glicoproteina-2-acetamido-2-desoxi-3-d-glucopiran osidasa.

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right

Effective date of registration: 20210621

Address after: No. 369, Yuzhou South Road, Lianyungang, Jiangsu Province

Applicant after: CHIA TAI TIANQING PHARMACEUTICAL GROUP Co.,Ltd.

Address before: No. 369, Yuzhou South Road, Lianyungang, Jiangsu Province

Applicant before: CHIA TAI TIANQING PHARMACEUTICAL GROUP Co.,Ltd.

Applicant before: Nanjing Mingde New Drug Development Co.,Ltd.

TA01 Transfer of patent application right
GR01 Patent grant
GR01 Patent grant